Canadian Reimbursement and Forecasting Timelines (CRaFT) Report

October 2021 Update

WHY DO YOU NEED THIS REPORT?

The Canadian Reimbursement and Forecasting Timelines (CRaFT) Report October 2021 update is a 100+ page PowerPoint resource complete with analysis and insights from trusted industry experts.

MORSE analyzed Canadian market access data to create key reimbursement metrics. The Report can support any organization that is planning a Canadian launch by providing critical timeline insights on the public market reimbursement process – from HTA submission to provincial listing.

WHAT DOES THE REPORT INCLUDE?

  • Analysis of pCPA process phase timelines
  • Negotiation trends
  • Provincial time-to-listing trends and market access timelines
  • Sub-analysis of data with stratification by oncology & non-oncology
  • CADTH and pCPA volume & Timeline metrics
  • pCPA Developments

The Report focuses on metrics from 2020 but also provides relevant comparisons to 2019 and 2018 to identify trends. In addition, it contains formulary listing information from 2019 & 2020 pCPA Completed Negotiations (current as of June 30, 2021).

FEEDBACK ON THIS REPORT

NEW! CRaFT ONCOLOGY AND BIOSIMILAR SUB-REPORT

Designed to accompany the MORSE CRaFT Report, the Oncology and Biosimilar Sub-Report provides a thorough analysis of Canadian market access timelines for IV oncology drugs compared to oral oncology drugs and the most up-to-date listing data for biosimilar drugs.

For further information on content and pricing, please complete the form below.

This report is only available to pharmaceutical companies to assist with their reimbursement forecasting and planning.


We're committed to your privacy. MORSE may use the information you provide to us to contact you about our relevant content and services. Your name, address and all other personal information will not be sold or given to any other organization or list distributor. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

Canadian Reimbursement and Forecasting Timelines Report, October 2021 Update